Eesti - eesti - Ravimiamet

actavis group ptc ehf. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 5ml 1tk; 2mg 1ml 10ml 1tk; 2mg 1ml 50ml 1tk; 2mg 1ml 25ml 1tk; 2mg 1ml 75ml 1tk; 2mg 1ml 100ml 1tk; 2mg 1ml 10ml 10tk; 2mg 1ml 5ml 10tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - doksorubitsiin - süstelahuse pulber - 10mg 1tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - doksorubitsiin - süstelahuse pulber - 50mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Eesti - eesti - Ravimiamet

accord healthcare b.v. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 10ml 1tk; 2mg 1ml 50ml 1tk; 2mg 1ml 25ml 1tk; 2mg 1ml 100ml 1tk; 2mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 100ml 1tk; 2mg 1ml 50ml 1tk; 2mg 1ml 25ml 1tk; 2mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 25ml 1tk; 2mg 1ml 100ml 1tk; 2mg 1ml 5ml 1tk; 2mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

pharmachemie b.v. - doksorubitsiin - infusioonilahuse kontsentraadi pulber - 50mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Euroopa Liit - eesti - EMA (European Medicines Agency)

baxter holding b.v. - doksorubitsiini vesinikkloriid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastilised ained - caelyx pegylated liposomal on näidatud:kui monotherapy patsientidel metastaatilise rinnavähi, kus on suurem südame riski;ravi kaugelearenenud munasarja vähk naistel, kes ei ole suutnud esimese-line platinum põhineva keemiaravi raviskeemi;koos bortezomib ravi järk-järgulise hulgimüeloom patsientidel, kes on saanud vähemalt ühe eelneva ravi ja kes on juba läbinud või on sobimatud luuüdi siirdamine;raviks aids-iga seotud kaposi on sarkoom (ks) patsientidel, kellel on madal cd4 loeb (.